Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
Interventions: Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate, Pharmacological Study, Therapeutic Conventional Surgery; Other · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 9 more

Conditions: Melanoma
Interventions: High-dose Interferon alfa-2b, Vemurafenib; Drug
Lead sponsor: John Kirkwood; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Scleroderma, Interstitial Lung Disease
Interventions: Mycophenolate mofetil, Cyclophosphamide, Placebo; Drug
Lead sponsor: Michael Roth; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more

Conditions: Neuroblastoma, Sarcoma
Interventions: Cabozantinib; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 18 Months to 40 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 6
States / cities: Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 3 more

Conditions: Ovulatory Dysfunction, Anovulation, Ovulation Induction
Interventions: clomiphene citrate; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Neuroblastoma, Lymphoma, High-risk Tumor
Interventions: CD133+ selected autologous stem cell infusion, IL-2, hu14.18K322A, Busulfan, Melphalan, GM-CSF, Bendamustine, Etoposide, Cytarabine, Carboplatin, Haploidentical natural killer cell infusion, G-CSF, Etoposide phosphate, CliniMACS; Biological · Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Obesity
Interventions: Intervention Control, Counselling, Contrave, Contrave and Counseling; Behavioral · Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Scottsbluff, Nebraska

Conditions: Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Interventions: bremelanotide; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 65
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 60 more

Conditions: Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
Interventions: Psilocybin (drug), Dextromethorphan (DXM); Drug
Lead sponsor: Jennifer Mitchell; Other
Eligibility: 50 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Urinary Bladder Neoplasms
Interventions: Nivolumab, BCG, BMS-986205; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 25
States / cities: Los Angeles, California • Riverside, California • San Francisco, California + 21 more

Conditions: HIV Infection
Interventions: Highly active antiretroviral therapy (HAART); Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 26
States / cities: Alhambra, California • Los Angeles, California • San Diego, California + 20 more

Conditions: High Grade Glioma, Anaplastic Astrocytoma
Interventions: DB107-RRV, DB107-FC; Drug
Lead sponsor: Ashish Shah; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment, HIV-Associated Cognitive Motor Complex
Interventions: Scopolamine Injectable Product, Mecamylamine Pill; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alzheimer Disease
Interventions: MK 6240; Drug
Lead sponsor: Tammie L. S. Benzinger, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Neuroblastoma, Neuroectodermal Tumors, Neoplasms
Interventions: 131I-MIBG, 131-MIBG + Vorinostat; Drug
Lead sponsor: Jubilant DraxImage Inc.; Industry
Eligibility: 1 Year and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 21
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 17 more

Conditions: Colorectal Cancer, Head and Neck Cancer
Interventions: Doxycycline, Hydrocortisone 1% cream, Sunscreen, Moisturizer, Clindamycin, Medrol-dose pack (Steroid); Drug · Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Focal Onset Seizures
Interventions: JNJ-40411813, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Tucson, Arizona • Orlando, Florida • Port Orange, Florida + 4 more

Conditions: Healthy
Interventions: Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose, gp140 DP High-dose, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 393 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more

Conditions: Influenza A, Influenza B
Interventions: Anti-Influenza Immune Plasma, Standard Care; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 35
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 22 more

Conditions: Prostate Cancer, Localized Prostate Carcinoma
Interventions: Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy; Drug · Diagnostic Test · Procedure
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cigarette Smoking
Interventions: Low-nitrosamine smokefree tobacco product for oral use, Non-tobacco, non-nicotine placebo product; Drug · Other
Lead sponsor: Swedish Match AB; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Daytona Beach, Florida • Evansville, Indiana • Portland, Oregon + 1 more

Conditions: Tonsillectomy
Interventions: Rocuronium, Sugammadex, Anesthesia without neuromuscular blockade; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Years to 12 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 99 Years
Enrollment: 9,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Multiple Locations, New Jersey

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Lamivudine, Sorbitol; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma

Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Traditional Clomiphene Citrate Administration vs. Stair-step Approach

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

A Study of Psychedelics in Healthy Older Adults With Low Well-being

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Mental Ability Challenge Study in Adults With and Without HIV

Study of Tau Imaging With the Use of [18F]MK-6240 Tracer

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Controlled Study of the Ability of a Smokefree Tobacco Product to Increase the Quit Rate Among Cigarette Smokers

Muscle Relaxation for Pediatric Adenotonsillectomy

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers